Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Dyadic International Inc. (DYAI : NSDQ)
 
 • Company Description   
Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms including humans found in the earth's biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic's `one-stop shop` technology rapidly discovers and expresses eukaryotic genes the genes of complex living organisms and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.10 Daily Weekly Monthly
20 Day Moving Average: 47,508 shares
Shares Outstanding: 28.26 (millions)
Market Capitalization: $59.35 (millions)
Beta: 0.46
52 Week High: $6.89
52 Week Low: $1.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.50% -1.46%
12 Week -43.55% -37.94%
Year To Date -53.54% -42.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
140 INTRACOASTAL POINTE DRIVE SUITE 404
-
JUPITER,FL 33477
USA
ph: 561-743-8333
fax: 561-743-8343
ir@dyadic.com http://www.dyadic.com
 
 • General Corporate Information   
Officers
Mark A. Emalfarb - President and Chief Executive Officer
Michael P. Tarnok - Chairman; Director
Ping W. Rawson - Chief Financial Officer
Jack L. Kaye - Director
Seth J. Herbst - Director

Peer Information
Dyadic International Inc. (CORR.)
Dyadic International Inc. (RSPI)
Dyadic International Inc. (CGXP)
Dyadic International Inc. (BGEN)
Dyadic International Inc. (GTBP)
Dyadic International Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 26745T101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 28.26
Most Recent Split Date: (:1)
Beta: 0.46
Market Capitalization: $59.35 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.23 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.62
Price/Cash Flow: -
Price / Sales: 22.91
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 40.00%
Sales Growth
vs. Year Ago Period: 40.56%
vs. Previous Quarter: 107.03%
ROE
03/31/22 - -61.46
12/31/21 - -58.65
09/30/21 - -43.62
ROA
03/31/22 - -54.44
12/31/21 - -52.34
09/30/21 - -39.82
Current Ratio
03/31/22 - 8.89
12/31/21 - 8.22
09/30/21 - 12.01
Quick Ratio
03/31/22 - 8.89
12/31/21 - 8.22
09/30/21 - 12.01
Operating Margin
03/31/22 - -473.45
12/31/21 - -543.68
09/30/21 - -443.68
Net Margin
03/31/22 - -473.45
12/31/21 - -543.68
09/30/21 - -443.68
Pre-Tax Margin
03/31/22 - -473.45
12/31/21 - -543.68
09/30/21 - -442.41
Book Value
03/31/22 - 0.58
12/31/21 - 0.65
09/30/21 - 0.78
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©